NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
New Orleans Hosts Psychedelic Research Conference Double-Header
Over the last week in February, more than 200 people from psychedelic drug development companies, clinical researchers, regulators, and investors gathered in New Orleans to attend the 6th Annual Psychedelic Therapeuti...
Turning On The Culture
Author and therapist Charles Wininger asks what would happen if millions of people across the political spectrum arose tomorrow and said ENOUGH of vitriol and demonization, suspicion and media-induced bitterness and h...
2026 First Quarter — Legislative Wrap Up
2026 will likely be an important year for psychedelic policy reform, with over a dozen states considering legislation and/or voter initiatives ranging from the creation of study commissions to the decriminalization of...
New Federal Bill Aims to Establish VA Office of Novel Therapeutics
The Veterans Health Administration Novel Therapeutics Preparedness Act is the fourth psychedelics-related bill filed in Congress this term as related legislation gains momentum. The post New Federal Bill Aims to Estab...
Europe’s Regulatory Body Signals Shift To ‘Weight of Evidence’ Model For Drug Approvals—How Does It Affect Psychedelic Medicines?
The European Medicines Agency is taking steps to rethink how certain high-need medicines reach patients, with a new concept paper proposing a more flexible, evidence-based pathway for cancer therapies. The post Europe...
Federal Support for U.S. Psychedelic Research Accelerates 5-MeO-DMT Clinical Trials
The rescheduling of cannabis by executive order and the FDA's acceleration of research into potential 5-MeO-DMT therapies reflects expanded federal support for clinical investigations into psychedelic-assisted treatme...
MAPS Sends Expert Delegation to United Nations Commission on Narcotic Drugs
Vienna, Austria; March 9, 2026 —The Multidisciplinary Association for Psychedelic Studies (MAPS) will send senior academics, advocates, Veterans, and policy experts to the 69th session of the United Nations Commission...
New RAND Report Shows Therapeutic Use Driving U.S. Views Towards Psychedelics
A new report from the RAND Corporation shows that nearly one-quarter of U.S. adults now support the legal use of psilocybin with public support driven by approval for therapeutic not personal access or recreational us...
Oregon’s Psilocybin Program: Industry Insiders Weigh In On Closures and the Future
Industry insiders weigh in on the growing pains of Oregon's regulated psilocybin program which has seen concerns raised about licensing fees and some service centers close. The post Oregon’s Psilocybin Program: Indust...
Varying Approaches to Psychedelic Policy Reform in Washington State
Lawmakers in Washington state have been debating two distinct and often conflicting visions for the regulation of psychedelics that reflects national tensions about the future of psychedelic therapies. The post Varyin...
Psychedelic-Assisted Therapies in Spanish Congress
On February 13, 2026, the Ernest Lluch Chamber of the Congress of Deputies hosted Spain’s first parliamentary conference dedicated to psychedelic-assisted psychotherapies. For four hours, the Spanish Parliament made r...
In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reform
Washington, DC; February 4, 2026 — With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a robust resource for psychedelic p...
Legislation, Industry, and the Future of Psilocybin for PTSD
The FDA acceptance of Compass Pathway’s Investigational New Drug Application for their COMP360 compound as a possible therapy for PTSD introduces a new area of possible therapies using psilocybin. The post Legislati...
NJ Psilocybin Legislation Exposes Conflicts Between Advocates for Different Therapeutic Models
The passage of New Jersey Assembly Bill 3852, which creates a psilocybin therapy pilot program, exposed deep rifts between advocates seeking a medicalized pharmaceutical-led model and those supporting a community-base...
What to Watch Out For in the Psychedelic Sector in 2026
Ismail Lourido Ali, JD, Co-Executive Director of The Multidisciplinary Association for Psychedelic Studies (MAPS), offers thoughts on what to watch out for in the psychedelic sector in 2026. The post What to Watch Ou...